HK1206642A1 - Method of adjuvant cancer treatment - Google Patents

Method of adjuvant cancer treatment

Info

Publication number
HK1206642A1
HK1206642A1 HK15107423.5A HK15107423A HK1206642A1 HK 1206642 A1 HK1206642 A1 HK 1206642A1 HK 15107423 A HK15107423 A HK 15107423A HK 1206642 A1 HK1206642 A1 HK 1206642A1
Authority
HK
Hong Kong
Prior art keywords
cancer treatment
adjuvant cancer
adjuvant
treatment
cancer
Prior art date
Application number
HK15107423.5A
Other languages
English (en)
Chinese (zh)
Inventor
Sylvie Laquerre
Peter F Lebowitz
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206642(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HK1206642A1 publication Critical patent/HK1206642A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
HK15107423.5A 2012-09-04 2015-08-03 Method of adjuvant cancer treatment HK1206642A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (1)

Publication Number Publication Date
HK1206642A1 true HK1206642A1 (en) 2016-01-15

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107423.5A HK1206642A1 (en) 2012-09-04 2015-08-03 Method of adjuvant cancer treatment

Country Status (21)

Country Link
US (6) US20150216868A1 (hu)
EP (2) EP3981408A1 (hu)
JP (3) JP2015527374A (hu)
KR (1) KR102134585B1 (hu)
CN (2) CN107308164A (hu)
AU (2) AU2013313050A1 (hu)
BR (1) BR112015004578A2 (hu)
CA (1) CA2882437C (hu)
CY (1) CY1124812T1 (hu)
DK (1) DK2892535T3 (hu)
ES (1) ES2900825T3 (hu)
HK (1) HK1206642A1 (hu)
HR (1) HRP20211817T1 (hu)
HU (1) HUE056646T2 (hu)
IN (1) IN2015KN00449A (hu)
LT (1) LT2892535T (hu)
PL (1) PL2892535T3 (hu)
PT (1) PT2892535T (hu)
RU (1) RU2640180C2 (hu)
SI (1) SI2892535T1 (hu)
WO (1) WO2014039375A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107308164A (zh) 2012-09-04 2017-11-03 诺华股份有限公司 辅助癌症治疗的方法
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
ES2952265T3 (es) * 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
US11890286B2 (en) * 2018-04-17 2024-02-06 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
JP2023506768A (ja) * 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005004286T2 (de) 2004-06-11 2009-01-02 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
EP1853250B1 (en) * 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
RS65800B1 (sr) * 2009-10-16 2024-08-30 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
CN107308164A (zh) 2012-09-04 2017-11-03 诺华股份有限公司 辅助癌症治疗的方法

Also Published As

Publication number Publication date
RU2640180C2 (ru) 2017-12-26
AU2016244279B2 (en) 2018-01-04
US20200054641A1 (en) 2020-02-20
US20180338979A1 (en) 2018-11-29
HUE056646T2 (hu) 2022-02-28
JP2019142899A (ja) 2019-08-29
DK2892535T3 (da) 2022-01-03
AU2013313050A1 (en) 2015-03-26
ES2900825T3 (es) 2022-03-18
US20210060021A1 (en) 2021-03-04
PT2892535T (pt) 2021-12-15
JP6684941B2 (ja) 2020-04-22
KR20150047619A (ko) 2015-05-04
EP3981408A1 (en) 2022-04-13
LT2892535T (lt) 2021-12-10
RU2015105821A (ru) 2016-10-20
JP2018058859A (ja) 2018-04-12
CA2882437A1 (en) 2014-03-13
WO2014039375A1 (en) 2014-03-13
CA2882437C (en) 2021-03-02
EP2892535A1 (en) 2015-07-15
CN107308164A (zh) 2017-11-03
IN2015KN00449A (hu) 2015-07-17
AU2016244279A1 (en) 2016-11-03
JP2015527374A (ja) 2015-09-17
US10869869B2 (en) 2020-12-22
US20170202842A1 (en) 2017-07-20
HRP20211817T1 (hr) 2022-03-04
CY1124812T1 (el) 2022-11-25
JP6511117B2 (ja) 2019-05-15
KR102134585B1 (ko) 2020-07-17
CN104582706A (zh) 2015-04-29
PL2892535T3 (pl) 2022-01-31
US20230330091A1 (en) 2023-10-19
EP2892535B1 (en) 2021-09-22
EP2892535A4 (en) 2016-04-13
BR112015004578A2 (pt) 2017-07-04
SI2892535T1 (sl) 2022-01-31
US20150216868A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL237791B (en) A method for treating cancer
SG11201503893RA (en) Method of treating cancer
EP2760452A4 (en) METHODS OF TREATING CANCER
IL232890A0 (en) Immunogenic therapy for cancer
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
EP2780033A4 (en) METHODS OF TREATING CANCER
HK1206642A1 (en) Method of adjuvant cancer treatment
HK1214128A1 (zh) 癌症的治療
HK1205254A1 (en) Methods of treatment of cancer
IL228430A0 (en) Cancer treatment
HK1204956A1 (en) Treatment of cancer
GB201217892D0 (en) Treatment of cancer
EP2849786A4 (en) METHOD FOR THE TREATMENT OF GASCULAR CANCER
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
GB201208296D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer